Comparative Pharmacology
Head-to-head clinical analysis: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE versus NUEDEXTA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE versus NUEDEXTA.
MEMANTINE HYDROCHLORIDE AND DONEPEZIL HYDROCHLORIDE vs NUEDEXTA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Memantine is an NMDA receptor antagonist, noncompetitively blocking glutamate-mediated excitotoxicity. Donepezil is a reversible acetylcholinesterase inhibitor, increasing acetylcholine levels in the brain.
NUEDEXTA is a combination of dextromethorphan (an NMDA receptor antagonist and sigma-1 receptor agonist) and quinidine (a CYP2D6 inhibitor). The mechanism by which dextromethorphan exerts therapeutic effects in pseudobulbar affect is unknown, but it is thought to involve modulation of glutamatergic neurotransmission via NMDA receptor antagonism and sigma-1 receptor agonism. Quinidine increases dextromethorphan plasma concentrations by inhibiting its CYP2D6-mediated metabolism.
Memantine ER/donepezil: 28 mg/10 mg orally once daily in the evening. Titrate from 7 mg/5 mg (or 14 mg/5 mg) over 4 weeks.
NUEDEXTA (dextromethorphan hydrobromide 20 mg / quinidine sulfate 10 mg) is administered orally once daily in the morning for 7 days, then increased to twice daily (every 12 hours).
None Documented
None Documented
Memantine: terminal half-life 60-80 hours, requiring dose titration to steady state in ~3-4 weeks. Donepezil: terminal half-life ~70 hours, achieving steady state in 14-21 days. Renal impairment prolongs memantine half-life; hepatic impairment affects donepezil.
Dextromethorphan: ~13 hours (range 9-19 hours) when co-administered with quinidine due to CYP2D6 inhibition; quinidine: ~6-8 hours. Clinical context: Steady-state achieved in approximately 3 days; half-life prolongation allows twice-daily dosing.
Memantine: ~75-90% excreted unchanged in urine via renal tubular secretion and glomerular filtration, with ~10% as metabolites. Donepezil: ~57% excreted in urine (17% unchanged) and ~15% in feces. Biliary excretion is minimal for both.
Renal excretion of unchanged drug and metabolites: dextromethorphan and metabolites (including dextrorphan) undergo renal elimination; quinidine is primarily hepatically metabolized, with <20% excreted unchanged in urine. Fecal elimination is minor (<5%).
Category A/B
Category C
NMDA Receptor Antagonist
NMDA Receptor Antagonist